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Abstract
Background: Anaphylaxis, a rare and potentially life-threatening hypersensitivity reaction, can 
occur after vaccination.
Objective: We sought to describe reports of anaphylaxis after vaccination made to the Vaccine 
Adverse Event Reporting System (VAERS) during 1990–2016.
Methods: We identified domestic reports of anaphylaxis within VAERS using a combination of 
Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed a 
descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and 
drug allergies) and vaccines given. We reviewed all serious reports and all nonserious reports with 
available medical records to determine if they met the Brighton Collaboration case definition for 
anaphylaxis or received a physician’s diagnosis.
Results: During the analytic period, VAERS received 467,960 total reports; 828 met the Brighton 
Collaboration case definition or received a physician’s diagnosis of anaphylaxis: 654 (79%) were 
classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged 
less than 19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 
reports in persons aged 19 years or greater, 80% were female, and influenza vaccines were most 
frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. 
We identified 8 deaths, 4 among persons with no history of hypersensitivity.
Conclusion: Anaphylaxis after vaccination is rare in the United States and can occur among 
persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious 
complications, including death, can occur. (J Allergy Clin Immunol 2019;143:1465–73.)
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Anaphylaxis is an acute hypersensitivity reaction that involves multiple organ systems and 
can present with variable severity, ranging from mild to life-threatening.1 Anaphylaxis 
occurs because of the sudden release of histamine, tryptase, and other mediators into the 
systemic circulation from mast cell and basophil granules.2 This release (also known as 
degranulation) most often occurs in persons with prior exposure to an antigen, where that 
exposure leads to production of IgE antibodies that bind mast cells and basophils, leading to 
degranulation on subsequent exposure to the same antigen (now allergen); direct 
degranulation through nonimmunologic mechanisms can also occur. The symptoms of 
anaphylaxis are many and can include generalized urticarial rash, airway swelling and 
difficulty breathing, hypotension, nausea, or vomiting. Anaphylaxis occurs in the United 
States with a rate as high as 100 cases per 100,000 population,3 leading to as many as 1000 
deaths annually.4
Anaphylaxis after vaccination is rare,5–7 and estimated occurrence varies with the 
surveillance systems used to obtain data. National active surveillance in the United Kingdom 
found a rate of 12 cases per 100,000 doses distributed after single-component measles 
vaccine among children aged less than 16 years.8 Reporting from selected health care 
organizations in the United States found an overall rate of anaphylaxis after vaccination of 
1.3 cases per million doses administered to both children and adults.9 Available data seem to 
suggest a particular patient profile for persons who experience anaphylaxis after vaccination: 
the vast majority have a history of atopy (ie, a history of atopic disease, such as asthma, 
allergic rhinitis, atopic dermatitis, or food or drug allergy).9 Despite the sometimes dramatic 
presentation of symptoms, almost all fully recover.8,9
The possibility remains that patients without a history of atopy or who do not fully recover 
exist but go undetected. Such knowledge might improve the awareness and management of 
anaphylaxis after vaccination. One strength of a national passive surveillance system is the 
ability to detect rare events occurring after vaccination post-licensure.10 To describe 
experiences and outcomes of anaphylaxis reported after vaccination, including affected 
populations that might have thus far been unrecognized, we reviewed data from a passive 
surveillance system in the United States.
METHODS
Data source
Health care providers, vaccine manufacturers, vaccine recipients, and other persons can 
report adverse events (AEs) after US-licensed vaccines to the Vaccine Adverse Event 
Reporting System (VAERS), a national spontaneous reporting system for monitoring AEs.
10,11
 Reported signs and symptoms are coded by using Medical Dictionary for Regulatory 
Activities (MedDRA) Preferred Terms (PTs).12 MedDRA PTs need not be medically 
confirmed diagnoses, and a VAERS report can be assigned multiple MedDRA PTs. Based 
on the Code of Federal Regulations, a report is classified as serious if 1 or more of the 
following conditions is reported: death, life-threatening illness, hospitalization or 
prolongation of existing hospitalization, permanent disability, or a congenital anomaly or 
birth defect.13 Because of these criteria, reported anaphylaxis might be of clinically severe 
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presentation but not necessarily classified as a serious report. Serious reports from vaccine 
manufacturers typically do not contain medical records that VAERS personnel can review: 
these reports of AEs are usually received by vaccine manufacturers directly, who 
subsequently request and review medical records per regulatory processes10 and then report 
the AEs to the VAERS as serious reports. For serious reports from nonmanufacturers, 
medical records are routinely requested and made available to VAERS personnel.
Descriptive analysis
We searched the VAERS database for reports of anaphylaxis after vaccination in the United 
States with a vaccination date of January 1, 1990, through December 31, 2016 (among 
reports received by the Centers for Disease Control and Prevention through February 28, 
2017). We conducted this search using 3 approaches of increasing specificity; each approach 
searched through all reports to VAERS during the specified period: (1) using the MedDRA 
System Organ Class (SOC; the highest level of the MedDRA hierarchy that provides the 
broadest classification for AEs) to identify reports involving the SOCs “skin and 
subcutaneous tissue disorders,” “immune system disorders,” and “respiratory, thoracic, and 
mediastinal disorders”;(2) using the Standardized MedDRA Query (SMQ) query (which 
identifies reports with any of a predetermined set of PTs) for “anaphylactic reaction” or 
“anaphylactic/anaphylactoid shock conditions”; and (3) identifying reports with the PTs 
“anaphylactic reaction,” “anaphylactic shock,” “anaphylactoid reaction,” and/or 
“anaphylactoid shock.” We also identified reports containing the following PTs in 
combinations that might meet the Brighton Criteria case definition for anaphylaxis: 
“angioedema,” “generalized erythema,” “urticaria,” “urticarial rash,” “cyanosis,” “grunting,” 
“stridor,” “tachypnea,” “wheezing,” “loss of consciousness,” “tachycardia,” “abdominal 
pain,” “diarrhea,” “nausea,” “vomiting,” and “tryptase increased.”
We reviewed all serious reports (including serious reports from vaccine manufacturers) and 
all nonserious reports (including from vaccine manufacturers) for which medical records 
were available that described cases of anaphylaxis meeting the Brighton Criteria case 
definition for anaphylaxis (Appendices A and B).14 We also reviewed cases that did not 
meet the Brighton Criteria case definition but received a physician’s diagnosis of 
anaphylaxis. We then limited analysis to reports describing symptoms within 1 day of 
receiving vaccine. We stratified the data by age group (<4 years, 4–10 years, 11–18 years, 
19–49 years, and ≥50 years), taking into account recommended vaccination schedules15,16 
and previous descriptions of anaphylaxis after vaccination related to age.5,9 For each age 
group, we analyzed reports by the seriousness of the report (serious or nonserious), sex, and 
time from vaccination to symptom onset. Reports were further analyzed by history of 
hypersensitivity (respiratory allergies, including allergic rhinitis, sinusitis, and bronchitis; 
asthma; anaphylaxis; and allergies to foods or medications) that have previously been 
described as risks for future anaphylaxis,17 including atopic dermatitis (which has been 
associated with food allergies and anaphylaxis18), treatment received, and whether vaccines 
were given alone or concomitantly with other vaccines.
Nonserious reports that were not reviewed (because they lacked medical records for review) 
still contained data for age, sex, days from vaccination to onset of symptoms, symptoms, and 
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vaccines received. For reports describing symptoms within 1 day of vaccination, we 
described distributions by age group, sex, reports potentially meeting the Brighton case 
definition, and vaccines administered.
Estimated rates of anaphylaxis for combined measles, mumps, and rubella vaccine (MMR); 
pneumococcal polysaccharide vaccine; and varicella vaccine were calculated by using 
reports received during the specified time period (eg, 2006–2016) as the numerator divided 
by doses distributed by their manufacturer19 during the same time period (Merck and 
Company, Whitehouse Station, NJ, personal communication) as the denominator. These 
rates were reported as reports per 1 million doses distributed. For influenza vaccine (all 
types), annual estimated rates of anaphylaxis were calculated by using reports received 
during the specified time period as the numerator and population estimates and vaccine 
coverage per year as the denominator,20,21 from which a median rate of cases per doses 
administered was estimated.
RESULTS
Of 467,960 reports to VAERS during the analytic period,22 we identified 282,249 reports to 
the VAERS database containing 1 or more of the MedDRA SOCs listed in the Methods 
section. SMQs reduced this number to 15,404 reports. To further increase the specificity of 
our query, we then limited our search to the PTs of “anaphylactic reaction,” “anaphylactic 
shock,” “anaphylactoid reaction,” “anaphylactoid shock,” and selected PTs in combinations 
that might meet the Brighton definition: this approach yielded 2,317 reports (including 
reports from vaccine manufacturers). Of these 2,317 reports, 1,090 were serious, and 1,227 
were nonserious. We reviewed all 1,090 serious reports and the 239 nonserious reports for 
which medical records were available: 863 either met the Brighton Collaboration case 
definition or included a diagnosis of anaphylaxis by a physician; 828 reports described 
symptoms within 1 day of receiving vaccine. Our analysis focused on these 828 reports.
Of the 828 reports that either met the Brighton case definition or included a diagnosis of 
anaphylaxis by a physician, and also described symptoms within 24 hours of receiving the 
vaccine, 654 (79%) were classified as serious (Table I), and 669 (81%) had medical records 
available for review. Median age for persons in these reports was 12 years (range, <1–86 
years); the 2 age groups with the most reports were aged 4 to 10 years and 19 to 49 years, 
respectively. Most persons aged less than 19 years were male (65%), whereas most persons 
aged 19 years or older were female (80%). Of reports with time to onset of symptoms 
available, 77% described symptoms less than 2 hours after vaccination: considering all age 
groups, median time to onset after vaccination was 20 minutes (range, <1 minute to 24 
hours). Most reports (85%) met either Brighton level 1 or 2 criteria (Appendices A and B).
Overall, 487 (59%) reports described persons with a history of hypersensitivity (Table II). 
The proportion of persons with a history of hypersensitivity increased with age group, from 
38% (persons aged <4 years) to 64% (persons aged 19–49 years). Persons aged less than 19 
years who had a history of hypersensitivity were mostly male (67%) and most commonly 
had respiratory allergies (62%); persons aged 19 years or greater were mostly female (71%), 
and they most commonly had drug allergies (64%), most frequently to penicillin (66 [46%] 
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reports). Most of these 487 persons with a history of hypersensitivity received treatment 
with antihistamines, epinephrine, and/or steroids: few reports (6%) did not document 
treatment. Time to onset of symptoms after vaccination was less than 2 hours for most 
persons with a history of hypersensitivity (70%).
Of 341 (41%) reports describing persons without a history of hypersensitivity, most (81%) 
were serious (Table III). These reports described persons aged less than 19 years who were 
mostly male (61%), and persons aged 19 years or older who were mostly female (72%). 
Most persons received treatment with antihistamines, epinephrine, and/or steroids; few 
reports (11%) did not document treatment. Time to onset of symptoms after vaccination was 
less than 2 hours for most persons without a history of hypersensitivity (68%).
Overall, the most commonly reported vaccines associated with reports of anaphylaxis were 
influenza vaccines (all types; 330 [40%] reports; Table IV). For persons aged less than 19 
years, MMR (196 reports), varicella vaccines (178 reports), and vaccines containing 
diphtheria toxoids, tetanus toxoids, and/or acellular pertussis (eg, combined diphtheria, 
tetanus, and acellular pertussis vaccine and combined tetanus, diphtheria, and acellular 
pertussis vaccine; 165 reports) were most commonly reported. For persons aged 19 years or 
greater, influenza vaccine (all types) was most commonly reported (224 reports). Among 
467 persons who received only a single vaccine, the most commonly reported vaccine was 
influenza vaccine (all types; 254 [54%] reports); among persons aged 4 to 10 years, varicella 
vaccine was reported nearly as frequently (29 reports, Table V). Among 171 persons who 
received only a single vaccine and had no history of hypersensitivity, the most commonly 
reported vaccines were influenza vaccines (all types; 83 [49%] reports), except among 
persons aged 4 to 10 years (for whom varicella vaccine was most common (11 [33%] 
reports) and among persons aged 11 to 18 years (for whom MMR was most common (3 
[23%] reports).
We identified 8 reports of death (Table VI). Of 7 reports with time to onset of symptoms 
available, 5 reported a time to onset of 20 minutes or less after vaccination. Described 
persons had a median age of 48 years (range, 42–84 years), 6 of whom received trivalent 
inactivated influenza vaccine. Half (50%) of reports described persons with no history of 
hypersensitivity, including the only death reported among persons aged less than 19 years (a 
2-year-old boy).
Of 988 nonserious reports that were not reviewed, 857 reported onset of symptoms within 1 
day of vaccination; 855 reported age data. Almost half of reports (411 [48%] reports) 
described combinations of symptoms that could potentially meet the Brighton Criteria case 
definition. Of 484 reports describing persons aged less than 19 years, most (57%) were 
male; of 391 reports describing persons aged 19 years or greater, most (79%) were female. 
Whether given with other vaccines (274 reports) or alone (229 reports), influenza vaccines 
(all types) were the most commonly reported vaccines.
The estimated rate of anaphylaxis reported to VAERS during 1990 to 2016 after MMR was 
0.6 per 1 million doses distributed, and after pneumococcal polysaccharide vaccine was 0.2 
per 1 million doses distributed; during 2006 to 2016, the estimated rate after varicella 
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vaccine was 1.2 per 1 million doses distributed. During 2010 to 2016, after influenza vaccine 
(all types) among persons aged 1 to 84 years, the median estimated annual rate was0.2 
(range, 0.1–0.4) per 1 million doses administered. When considering only reports meeting 
Brighton Collaboration case certainty levels 1 and 2 (ie, cases with high diagnostic certainty 
of anaphylaxis), the median estimated annual rate after influenza vaccine (all types) 
decreased to 0.1 (range, 0.1–0.4) per 1 million doses administered; all other estimated rates 
remained unchanged. Notably, the 411 unreviewed nonserious reports that could meet the 
Brighton Criteria case definition could increase included reports by 50%; however, 173 
(72%) of 239 nonserious reports that were reviewed met the Brighton case definition. 
Assuming a 72% increase in estimated rates to account for potentially missed nonserious 
reports that might have met the Brighton case definition, the estimated rate of anaphylaxis 
after MMR would be 1.1, after pneumococcal polysaccharide vaccine would be 0.3, and 
after varicella vaccine would be 2.1 per 1 million doses distributed; after influenza vaccine 
(all types), the median estimated annual rate would increase to 0.3 (range, 0.2–0.8) per 1 
million doses administered.
DISCUSSION
Anaphylaxis after vaccination is a rarely reported event in the United States, with a reported 
rate of 1.3 cases per 1 million doses administered.9 The data in this report reflect this rarity 
and are consistent with analyses of other passive reporting systems describing the frequency 
of anaphylaxis after vaccination.8,23 Given this rarity, anaphylaxis after vaccination severe 
enough to cause death is an exceptionally rare outcome.
Some findings in this analysis are consistent with previous observations. The predominance 
of male sex in younger age groups (eg, aged <19 years) and female sex in older age groups 
(eg, aged ≥19 years) has been observed in previous analyses.9,24,25 Most reports in this 
analysis (67%) noted symptoms less than 2 hours after vaccination (Table I), which is 
consistent with the rapid development of symptoms described by other investigators.9,26 
Reported histories of hypersensitivity were also similar to histories described by other 
investigators, including respiratory allergies, such as asthma and drug allergies.27–29 
Although histories of sensitivity to penicillin or cephalosporins were commonly reported, 
vaccines do not contain these antibiotics; therefore patients with such sensitivities might be 
predisposed to allergic reactions in general. Notably, a history of asthma can increase the 
likelihood of a severe or even fatal episode of anaphylaxis.30
Contrasting previous reports,5,9 many persons with reported anaphylaxis after vaccination 
(41%) described no history of hypersensitivity (Table III). Such persons did not appreciably 
differ from persons with a reported history of hypersensitivity (eg, similar proportions by sex 
and age group; Table II), including time to onset of symptoms. Regardless of history of 
hypersensitivity, similar proportions of patients received drug treatment (≥89%). We 
observed a somewhat greater proportion of persons indicating treatment with epinephrine 
relative to other reports.9,31 This difference might reflect the passive reporting nature of 
VAERS but might also reflect a diverse range of symptom severity, with some persons 
experiencing symptoms mild enough to be managed with other medications (eg, steroids and 
antihistamines) despite epinephrine’s status as a first-line treatment for anaphylaxis.9,32 
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These observations underscore current recommendations that any provider administering 
vaccines should have emergency protocols and supplies on hand, including epinephrine, 
should a patient develop anaphylaxis.33
Vaccines for which anaphylaxis was reported reflected the recommended vaccine schedule 
for persons of the patient’s age (Tables IV and V). Multiple vaccines are routinely 
recommended for persons aged less than 19 years and are often given at the same provider 
visit33; the vaccines that were commonly reported for this age group in our analysis reflect 
the age-appropriate recommended vaccines (eg, MMR and combined diphtheria, tetanus, 
and acellular pertussis vaccine). Persons aged 19 years or greater tend to receive relatively 
fewer vaccines (except for influenza vaccine, which is recommended annually15) and might 
have greater opportunity to receive such vaccines singly. The predominance of reports of 
influenza vaccine in persons aged 19 years or greater might reflect the relatively greater 
frequency of administering this vaccine compared with other vaccines. Notably, anaphylaxis 
after hepatitis A vaccine had not been reported previously.34 Reports of anaphylaxis after 
hepatitis A vaccine within VAERS but not in other surveillance mechanisms9 reflect the 
increased sensitivity of a nationwide passive surveillance system like VAERS.
Of the 8 reports describing anaphylaxis and death after vaccination, 6 were documented 
previously35; the other 2 reports (describing the boy aged 2 years and the woman aged 43 
years) had not been described before this analysis. The rapid onset of symptoms after 
vaccination (within 20 minutes) in many cases suggests vaccine played a role in these 
episodes of anaphylaxis,36 but other factors might have played a role (eg, the patient with 
allergies to penicillin who received ceftriaxone before vaccination). Half of these deaths 
occurred in persons with no history of hypersensitivity, underscoring the need for vigilance 
of all vaccinated persons and to be prepared for immediate intervention, if needed.33
McNeil et al9 reviewed diagnoses of anaphylaxis among persons of all ages enrolled in 
health plans during January 2009 to December 2011. Diagnoses of anaphylaxis were 
identified by using International Classification of Diseases, Ninth Revision, codes and 
review of medical records: 33 persons were identified with anaphylaxis (Brighton level 1 or 
2) associated with vaccination, with an estimated overall incidence of 1.31 cases of 
anaphylaxis per million doses of vaccine administered (including rates of 5.1 and 5.8 cases 
per million doses administered for MMR and varicella vaccines, respectively).9 Because 
VAERS does not collect data on doses administered, our estimated rates used either doses 
distributed or vaccination coverage as a denominator. Our comparatively lower rates reflect 
this larger denominator, as well as incomplete reporting to VAERS (including possible 
episodes of anaphylaxis that were aborted before development of symptoms that would 
fulfill Brighton case certainty criteria). These 2 analyses provide complementary 
information on anaphylaxis after vaccination: although both analyses applied Brighton 
Criteria and reviewed medical records (when possible), the greater volume of reports within 
VAERS allowed a greater ability to detect events, whereas data from McNeil et al9 allowed a 
more robust estimation of risk.
Our analysis has limitations. VAERS is a passive reporting system and is subject to 
limitations like underreporting, reporting biases, inconsistent data quality and completeness, 
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changes in reporting over time, and lack of an unvaccinated comparison group.11,37 For 
these reasons, VAERS data generally cannot establish whether a vaccine caused a particular 
AE, including anaphylaxis.10 A broader search including more PTs could potentially capture 
more reports of anaphylaxis within VAERS. Our results suggest reviewing nonserious 
reports without available medical records could increase included reports by 411 reports. 
Assuming all 411 reports included a history of hypersensitivity, a minimum of 341 (28%) of 
1239 reports would describe persons without a history of hypersensitivity, still a substantial 
proportion of reports. Furthermore, even assuming estimated rates increased by 72% to 
account for potentially missed reports, estimated rates of anaphylaxis after selected vaccines 
remained well below previously reported estimates.5,9 As mentioned, VAERS does not 
collect data on doses administered and estimated rates based on doses distributed are likely 
underestimates. Despite these limitations, VAERS remains a valuable tool for detecting 
unusual or unexpected patterns of reported AEs that might indicate vaccine safety concerns 
that warrant further investigation.38,39
Although rare after vaccination (1.3 cases per 1 million doses administered), anaphylaxis 
can be a life-threatening event. For this reason, vaccine safety surveillance systems 
specifically monitor for this outcome.5,9 Awareness of anaphylaxis after vaccination (and its 
potentially severe outcomes) can improve both detection and reported data quality of 
anaphylaxis after vaccination. Fortunately, the data in this analysis and elsewhere indicate 
that anaphylaxis after vaccination (and the possibility of death) is a rare event.
APPENDIX A.: Summary of Brighton Collaboration case definition for 
anaphylaxis14*
For all levels of diagnostic certainty, anaphylaxis is a clinical syndrome characterized by sudden onset, rapid 
progression of signs and symptoms, AND involving multiple (≥2) organ systems, as follows:
Level 1 of diagnostic certainty
 • ≥1 major dermatologic AND
 • ≥1 major cardiovascular AND/OR ≥1 major respiratory criterion
Level 2 of diagnostic certainty
 • ≥1 major cardiovascular AND ≥1 major respiratory criterion
OR
 • ≥1 major cardiovascular OR respiratory criterion AND
  1. ≥1 minor criterion involving ≥1 different system (other than cardiovascular or respiratory systems)
OR
  2. (≥1 major dermatologic) AND (≥1 minor cardiovascular AND/OR minor respiratory criterion)
Level 3 of diagnostic certainty
 • ≥1 minor cardiovascular OR respiratory criterion
AND
 • ≥1 minor criterion from each of ≥2 different systems/categories
This appendix describes the criteria for each level of diagnostic certainty specified in the Brighton Collaboration case 
definition for anaphylaxis.
*
The case definition should be applied when there is no clear alternative diagnosis for the reported event to account for the 
combination of symptoms.
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APPENDIX B.: Major and minor criteria used in Brighton Collaboration case 
definition for anaphylaxsis14*
Major criteria Minor criteria
Dermatologie or mucosal • Generalized urticaria (hives) or 
generalized erythema
• Angioedema,* localized or 
generalized
• Generalized pruritus with skin 
rash
• Generalized pruritus 
without skin rash
• Generalized prickle 
sensation
• Localized injection-site 
urticaria
• Red and itchy eyes
Cardiovascular • Measured hypotension
• Clinical diagnosis of 
uncompensated shock indicated 
by the combination of ≥3 of the 
following:
– tachycardia
– capillary refill time 
>3 s
– reduced central pulse 
volume
– decreased level or 
loss of 
consciousness
• Reduced peripheral 
circulation, as indicated 
by the combination of ≥2 
of the following:
– tachycardia, 
and
– capillary refill 
time >3 s 
without 
hypotension
– decreased level 
of 
consciousness
Respiratory • Bilateral wheeze 
(bronchospasm)
• Stridor
• Upper airway swelling (lip, 
tongue, throat, uvula, or larynx)
• Respiratory distress, ≥2 of the 
following:
– tachypnea
– increased use of 
accessory muscles 
(eg, 
sternocleidomastoid 
and intercostals)
– recession
– cyanosis
– grunting
• Persistent dry cough
• Hoarse voice
• Difficulty breathing 
without wheeze or stridor
• Sensation of throat closure
• Sneezing, rhinorrhea
Gastrointestinal • Diarrhea
• Abdominal pain
• Nausea
• Vomiting
Laboratory • Mast cell tryptase level 
increase > upper normal 
limit
This appendix describes the signs and symptoms by organ system that are considered major and minor criteria.
*Not hereditary angioedema.
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Abbreviations used
AE Adverse event
MedDRA Medical Dictionary for Regulatory Activities
MMR Combined measles, mumps, and rubella vaccine
PPVS23 Pneumococcal polysaccharide vaccine
PT Preferred Term
SOC System Organ Class
VAERS Vaccine Adverse Event Reporting System
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Clinical implications:
Anaphylaxis of severe or life-threatening severity is very uncommon but can occur, even 
among persons without a history of hypersensitivity; vaccine providers should be 
prepared to respond immediately.
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